We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multi-Bay Modular Real Time PCR Instrument Enables Rapid Onsite Nucleic Acid Testing

By LabMedica International staff writers
Posted on 02 Nov 2023
Print article
Image: The MQx96 96-well multi-bay modular qPCR instrument (Photo courtesy of Anitoa Systems)
Image: The MQx96 96-well multi-bay modular qPCR instrument (Photo courtesy of Anitoa Systems)

A new generation of compact and inexpensive molecular testing platforms features a unique ultra-low-light CMOS sensor technology that enables the detection of infectious or oncology markers, as well as pathogens in the food and environment.

Anitoa Systems (Sunnyvale, CA, USA) has launched new 96-well multi-bay modular real-time PCR (qPCR) instruments in its Maverick line of qPCR products. Anitoa's Maverick multi-bay modular qPCR instrument MQx96 is the company’s first larger format qPCR instrument that comes with multiple independently operable modules. The MQx96 and MQx48 instruments are available in 96 (6X16) and 48 (3X16) well formats, and feature 6X or 3X 16-well qPCR modules, both of which can be independently controlled using a unified software interface. MQx96 is ideal for laboratories that are required to run small sample batches continuously in a pipelined manner.

Maverick qPCR instruments feature technological innovations, including a unique proprietary low-light complementary metal-oxide-semiconductor (CMOS) 4-channel fluorescence optics system that enables rapid and highly multiplexed DNA detection. Additionally, Maverick qPCR instruments are easy to use and do not need calibration, thanks to their solid-state construction. Apart from their operational flexibility, Anitoa's MQ96 (and MQ48) are modular systems with each reaction chamber independently heated and cooled. This enables the instruments to achieve a 30-40% faster reaction time compared to traditional large-block qPCR systems.

"We are excited to offer laboratories worldwide a modular solution for rapid and pipelined nucleic acid tests to help combat diseases by detecting pathogens in human, as well as our food and environment," said Dr. Zhimin Ding, CEO of Anitoa Systems. "We believe our multi-bay modular qPCR instruments and the integrated software offer features that meet the needs of labs seeking higher throughput testing while being extremely flexible."

Related Links:
Anitoa Systems

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.